TN2019000033A1 - Agents thérapeutiques pour maladies neurodégénératives - Google Patents

Agents thérapeutiques pour maladies neurodégénératives

Info

Publication number: TN2019000033A1
Authority: TN; Tunisia
Prior art keywords: neurodegenerative diseases; therapeutic agents; leucine; present disclosure; pharmaceutically acceptable
Prior art date: 2016-08-11

Application number

TNP/2019/000033A

Other languages

English (en)

Inventor

Michael Strupp

Original Assignee

Intrabio Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-11

Filing date

2017-08-11

Publication date

2020-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2019000033(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-08-11 Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en

2017-02-16 Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en

2017-04-10 Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en

2017-04-28 Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en

2017-08-11 Application filed by Intrabio Ltd filed Critical Intrabio Ltd

2020-07-15 Publication of TN2019000033A1 publication Critical patent/TN2019000033A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Addiction (AREA)
Transplantation (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP/2019/000033A 2016-08-11 2017-08-11 Agents thérapeutiques pour maladies neurodégénératives TN2019000033A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB1613829.9A GB201613829D0 (en)	2016-08-11	2016-08-11	Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en)	2017-02-16	2017-02-16	Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1705766.2A GB201705766D0 (en)	2017-04-10	2017-04-10	Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1706867.7A GB201706867D0 (en)	2017-04-28	2017-04-28	Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
PCT/IB2017/054929 WO2018029658A1 (fr)	2016-08-11	2017-08-11	Agents thérapeutiques pour maladies neurodégénératives

Publications (1)

Publication Number	Publication Date
TN2019000033A1 true TN2019000033A1 (fr)	2020-07-15

Family

ID=59859424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP/2019/000033A TN2019000033A1 (fr)	2016-08-11	2017-08-11	Agents thérapeutiques pour maladies neurodégénératives

Country Status (28)

Country	Link
US (3)	US12144792B2 (fr)
EP (3)	EP3583940A1 (fr)
JP (3)	JP6957602B2 (fr)
KR (4)	KR20250042197A (fr)
CN (3)	CN116492328A (fr)
AU (3)	AU2017308865B2 (fr)
BR (1)	BR112019002730A2 (fr)
CA (1)	CA3033564A1 (fr)
CY (1)	CY1121930T1 (fr)
DK (1)	DK3416631T3 (fr)
ES (1)	ES2733677T3 (fr)
HR (1)	HRP20191055T1 (fr)
HU (1)	HUE045043T2 (fr)
IL (3)	IL310799A (fr)
LT (1)	LT3416631T (fr)
MA (2)	MA47521A (fr)
MD (1)	MD3416631T2 (fr)
ME (1)	ME03454B (fr)
MX (3)	MX383499B (fr)
PL (1)	PL3416631T3 (fr)
PT (1)	PT3416631T (fr)
RS (1)	RS59048B1 (fr)
RU (1)	RU2756519C2 (fr)
SG (1)	SG11201901063SA (fr)
SI (1)	SI3416631T1 (fr)
SM (1)	SMT201900370T1 (fr)
TN (1)	TN2019000033A1 (fr)
WO (1)	WO2018029658A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10219815B2 (en)	2005-09-22	2019-03-05	The Regents Of The University Of Michigan	Histotripsy for thrombolysis
EP3313517B1 (fr)	2015-06-24	2023-06-07	The Regents Of The University Of Michigan	Systèmes de thérapie par histotripsie pour le traitement de tissu cérébral
RS61442B1 (sr)	2016-08-11	2021-03-31	Intrabio Ltd	Farmaceutske kombinacije i upotrebe usmerene na poremećaje lizozomalnog skladištenja
RS59048B1 (sr)	2016-08-11	2019-08-30	Intrabio Ltd	Terapeutski agensi za neurodegenerativne bolesti
GB201709459D0 (en)	2017-06-14	2017-07-26	Intrabio Ltd	Treatment for migraine
CN111542314B (zh) *	2017-10-18	2023-11-24	内在生物技术有限公司	神经退行性疾病的治疗剂
WO2019159110A1 (fr)	2018-02-15	2019-08-22	Intrabio Ltd	Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
CN113348018B (zh) *	2018-12-06	2025-04-01	内在生物技术有限公司	乙酰基-亮氨酸的氘代类似物
MX2021010568A (es)	2019-03-02	2021-11-12	Intrabio Ltd	Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
JP7432711B2 (ja) *	2019-09-17	2024-02-16	エフ．ホフマン－ラロシュアーゲー	動作障害患者に対する個別化医療の改善
WO2021144720A1 (fr) *	2020-01-13	2021-07-22	Intrabio Ltd	Traitement de maladies neurodégénératives tardives chez des porteurs de mutations hétérozygotes du gène npc1
WO2022264037A1 (fr) *	2021-06-14	2022-12-22	Intrabio Ltd.	Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie
WO2024092272A1 (fr)	2022-10-28	2024-05-02	Histosonics, Inc.	Systèmes et procédés d'histotripsie
AU2024257180A1 (en)	2023-04-20	2025-09-18	Histosonics, Inc.	Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025151578A1 (fr) *	2024-01-12	2025-07-17	Intrabio Inc.	N-acétyl-leucine destinée à être utilisée dans le traitement d'alpha-synucléinopathies prodromales
WO2025163129A1 (fr) *	2024-02-01	2025-08-07	Intrabio Ltd.	Acétylleucine pour le traitement de la maladie de parkinson
US12403111B2 (en)	2024-02-02	2025-09-02	SynGAP Research Fund	Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060063827A1 (en)	2004-09-23	2006-03-23	Yu Ruey J	Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) *	2004-04-01	2005-10-06	Zeldis Jerome B	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) *	2006-09-13	2010-01-15	Pf Medicament	Traitement des vertiges par l'acetyl-l-leucine.
WO2008101693A2 (fr)	2007-02-22	2008-08-28	Beiersdorf Ag	Applications cosmétiques et pharmaceutiques d'acides aminés n-acylés, et composés structurellement apparentés
TN2010000251A1 (fr) *	2010-06-03	2011-11-11	Rekik Raouf	N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) *	2010-12-03	2012-05-24	Rekik Raouf	Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
SG11201603376UA (en) *	2013-10-28	2016-05-30	Naurex Inc	Nmda receptor modulators and prodrugs, salts, and uses thereof
SMT202400459T1 (it)	2016-04-19	2025-01-14	Intrabio Ltd	Acetil-leucina o un suo sale farmaceuticamente accettabile per mobilità migliorata
RS59048B1 (sr)	2016-08-11	2019-08-30	Intrabio Ltd	Terapeutski agensi za neurodegenerativne bolesti

2017
- 2017-08-11 RS RS20190801A patent/RS59048B1/sr unknown
- 2017-08-11 EP EP19174007.5A patent/EP3583940A1/fr active Pending
- 2017-08-11 PT PT17767934T patent/PT3416631T/pt unknown
- 2017-08-11 EP EP17767934.7A patent/EP3416631B1/fr active Active
- 2017-08-11 LT LTEP17767934.7T patent/LT3416631T/lt unknown
- 2017-08-11 RU RU2019106506A patent/RU2756519C2/ru active
- 2017-08-11 MA MA047521A patent/MA47521A/fr unknown
- 2017-08-11 CN CN202310629563.6A patent/CN116492328A/zh active Pending
- 2017-08-11 WO PCT/IB2017/054929 patent/WO2018029658A1/fr not_active Ceased
- 2017-08-11 PL PL17767934T patent/PL3416631T3/pl unknown
- 2017-08-11 DK DK17767934.7T patent/DK3416631T3/da active
- 2017-08-11 KR KR1020257008819A patent/KR20250042197A/ko active Pending
- 2017-08-11 SG SG11201901063SA patent/SG11201901063SA/en unknown
- 2017-08-11 CA CA3033564A patent/CA3033564A1/fr active Pending
- 2017-08-11 MA MA43828A patent/MA43828B1/fr unknown
- 2017-08-11 KR KR1020247014635A patent/KR102785448B1/ko active Active
- 2017-08-11 MX MX2019001575A patent/MX383499B/es unknown
- 2017-08-11 BR BR112019002730-0A patent/BR112019002730A2/pt not_active Application Discontinuation
- 2017-08-11 IL IL310799A patent/IL310799A/en unknown
- 2017-08-11 MD MDE20190027T patent/MD3416631T2/ro unknown
- 2017-08-11 JP JP2019507819A patent/JP6957602B2/ja active Active
- 2017-08-11 IL IL310801A patent/IL310801A/en unknown
- 2017-08-11 SM SM20190370T patent/SMT201900370T1/it unknown
- 2017-08-11 AU AU2017308865A patent/AU2017308865B2/en active Active
- 2017-08-11 ME MEP-2019-169A patent/ME03454B/fr unknown
- 2017-08-11 HU HUE17767934A patent/HUE045043T2/hu unknown
- 2017-08-11 KR KR1020197007032A patent/KR102413756B1/ko active Active
- 2017-08-11 IL IL264641A patent/IL264641B2/en unknown
- 2017-08-11 CN CN202310627214.0A patent/CN116459244A/zh active Pending
- 2017-08-11 KR KR1020227021012A patent/KR20220093385A/ko not_active Ceased
- 2017-08-11 US US16/324,353 patent/US12144792B2/en active Active
- 2017-08-11 SI SI201730071T patent/SI3416631T1/sl unknown
- 2017-08-11 HR HRP20191055TT patent/HRP20191055T1/hr unknown
- 2017-08-11 CN CN201780059708.6A patent/CN109789114A/zh active Pending
- 2017-08-11 ES ES17767934T patent/ES2733677T3/es active Active
- 2017-08-11 TN TNP/2019/000033A patent/TN2019000033A1/fr unknown
- 2017-08-11 EP EP24191483.7A patent/EP4467195A3/fr active Pending
2019
- 2019-02-07 MX MX2021006901A patent/MX2021006901A/es unknown
- 2019-07-16 CY CY20191100759T patent/CY1121930T1/el unknown
2021
- 2021-10-06 JP JP2021164793A patent/JP2022003085A/ja active Pending
2023
- 2023-03-15 US US18/183,972 patent/US20230210799A1/en active Pending
- 2023-04-05 AU AU2023202121A patent/AU2023202121B2/en active Active
- 2023-09-08 JP JP2023146465A patent/JP2023175762A/ja active Pending
2024
- 2024-01-12 US US18/411,512 patent/US20240189267A1/en active Pending
- 2024-04-11 MX MX2024004439A patent/MX2024004439A/es unknown
2025
- 2025-03-21 AU AU2025202077A patent/AU2025202077A1/en active Pending

Also Published As

Publication number	Publication date
US20200179320A1 (en)	2020-06-11
RU2756519C2 (ru)	2021-10-01
RU2021128045A (ru)	2021-11-16
IL264641A (en)	2019-04-30
IL264641B2 (en)	2024-07-01
KR20190039227A (ko)	2019-04-10
JP2023175762A (ja)	2023-12-12
AU2025202077A1 (en)	2025-04-10
CY1121930T1 (el)	2020-10-14
ME03454B (fr)	2020-01-20
US12144792B2 (en)	2024-11-19
IL310799A (en)	2024-04-01
US20230210799A1 (en)	2023-07-06
IL310801A (en)	2024-04-01
KR102785448B1 (ko)	2025-03-21
AU2017308865A1 (en)	2019-02-21
SMT201900370T1 (it)	2019-09-09
HRP20191055T1 (hr)	2019-09-06
AU2017308865B2 (en)	2023-04-13
IL264641B1 (en)	2024-03-01
KR20240068761A (ko)	2024-05-17
EP4467195A3 (fr)	2025-03-19
JP6957602B2 (ja)	2021-11-02
MD3416631T2 (ro)	2019-09-30
MA43828B1 (fr)	2019-09-30
JP2019524822A (ja)	2019-09-05
KR20250042197A (ko)	2025-03-26
WO2018029658A1 (fr)	2018-02-15
AU2023202121B2 (en)	2025-01-23
CN116459244A (zh)	2023-07-21
EP3416631A1 (fr)	2018-12-26
MX2024004439A (es)	2025-11-03
ES2733677T3 (es)	2019-12-02
US20240189267A1 (en)	2024-06-13
PL3416631T3 (pl)	2019-11-29
RU2019106506A3 (fr)	2020-10-29
KR102413756B1 (ko)	2022-06-27
JP2022003085A (ja)	2022-01-11
KR20220093385A (ko)	2022-07-05
MX2021006901A (es)	2021-07-07
RS59048B1 (sr)	2019-08-30
EP3416631B1 (fr)	2019-05-15
CN109789114A (zh)	2019-05-21
DK3416631T3 (da)	2019-07-15
PT3416631T (pt)	2019-07-11
CA3033564A1 (fr)	2018-02-15
HUE045043T2 (hu)	2019-12-30
MA43828A (fr)	2018-12-26
LT3416631T (lt)	2019-08-26
MX383499B (es)	2025-03-14
SI3416631T1 (sl)	2019-09-30
MX2019001575A (es)	2019-08-01
BR112019002730A2 (pt)	2019-05-14
RU2019106506A (ru)	2020-09-17
EP3583940A1 (fr)	2019-12-25
SG11201901063SA (en)	2019-03-28
AU2023202121A1 (en)	2023-05-04
EP4467195A2 (fr)	2024-11-27
MA47521A (fr)	2021-04-21
CN116492328A (zh)	2023-07-28

Publication	Publication Date	Title
MX2024004439A (es)	2025-11-03	Agentes terapeuticos para enfermedades neurodegenerativas
GB201820166D0 (en)	2019-01-23	Therapeutic agents
GB201820165D0 (en)	2019-01-23	Therapeutic agents
GB201909190D0 (en)	2019-08-07	Therapeutic agents
GB201909191D0 (en)	2019-08-07	Therapeutic agents
GB201909194D0 (en)	2019-08-07	Therapeutic agents
PH12017500493A1 (en)	2017-08-07	Combination therapy
MX379043B (es)	2025-03-10	Uso de sobetirome en el tratamiento de enfermedades de mielinización.
GB201902277D0 (en)	2019-04-03	Therapeutic agents
EA201892265A1 (ru)	2019-04-30	Способы лечения офтальмологических заболеваний
GB201805816D0 (en)	2018-05-23	Therapeutic agents
IL273929A (en)	2020-05-31	Therapeutic agents for neurodegenerative diseases
BR112019004791A2 (pt)	2019-06-04	tratamento de esclerose múltipla com chs-131
GB201906804D0 (en)	2019-06-26	Therapeutic agents
EP3508214A4 (fr)	2020-05-13	Agent thérapeutique pour maladies ischémiques.
HK40112206A (en)	2025-01-17	Therapeutic agents for neurodegenerative diseases
HK40111843A (en)	2025-01-10	Therapeutic agents for neurodegenerative diseases
GB201820164D0 (en)	2019-01-23	Therapeutic agents
GB201820162D0 (en)	2019-01-23	Therapeutic agents
GB201820160D0 (en)	2019-01-23	Therapeutic agents
GB201820170D0 (en)	2019-01-23	Therapeutic agents
GB201820168D0 (en)	2019-01-23	Therapeutic agents
GB201820172D0 (en)	2019-01-23	Therapeutic agents
GB201811753D0 (en)	2018-08-29	Therapeutic agents
GB201811467D0 (en)	2018-08-29	Therapeutic agents